Pedro Lichtinger is set to become Optimer Pharmaceuticals' president and CEO. He also will join the company's board of directors.
Julian Chick has resigned from the board of Avexa and will leave his position as the CEO at the end of the month.
Strides Arcolab has tapped Manish Gupta as CEO of its pharma business.
InteKrin Therapeutics has named Linda Slanec Higgins as its president and CEO.
The board of BioPhausia has appointed Maris Hartmanis as the company's new CEO.
Coronado Biosciences has named Gary Gemignani as COO and CFO.
Ampio Pharmaceuticals has tapped Bruce Miller to become its new CFO. In addition, Michael Macaluso will become chairman of the board of directors, replacing David Bar-Or, who remains the chief scientific officer and a member of the board.
Radient Pharmaceuticals has announced the appointment of Afsaneh Motamed-Khorasani as director of oncology.
Officials of Kylin Therapeutics report that Henry Li will serve in the newly created position as director for the company's R&D team.
Fate Therapeutics has named Tom Novak as VP of research and drug discovery.
N30 Pharma has expanded its board of directors, adding Howard Furst of Deerfield Management.